A consortium of 24 banks has lent a total of over Rs 3,200 crore to the drug maker and the lenders will be taking a haircut of around 65%.

Taking its chance, Accord, which had lost out to Dhanuka, filed a petition on June 14 asking for its bid to be considered.

Besides Dhanuka, two other companies - Accord Life Spec and Covalent Laboratories - had bid for Chennai-based Orchid Pharma in a second rou...

“After the amendment, Section 74 of the insolvency code prescribes stringent punishment to resolution applicant if it fails to implement a ...

Ruchi Soya owes Rs 9,405 crore to lenders and Rs 1,248 crore to operational creditors.

The drug maker was among the 28 companies that the RBI mandated banks to refer to bankruptcy court by December 2017.

Orchid Pharma was referred to the bankruptcy court by Lakshmi Vilas Bank after it failed to pay about Rs 3,500 crore to lenders.

Here is a list of top stocks that are likely to be in focus in today's trading session.

The resolution professional who is in charge of the management of the Chennai-based company has set April 25 as the fresh date for submitti...

In August, the Reserve Bank had asked banks to either resolve the 28 more large stressed accounts or refer them to the NCLT by December 31.

Orchid was on the Reserve Bank of India's second list of 28 defaulters that had to be referred to the NCLT before December 31 if no resolut...

28 bad loan accounts need restructuring by December 13 or they’ll end up in NCLT, which will require banks to provide for losses of up to 5...

Lakshmi Vilas Bank has referred Orchid Pharma to National Company Law Tribunal and the court had admitted the company on August 17.

In August, the NCLT Chennai had given the nod for insolvency proceedings against the company based on a plea filed by one of the lenders, L...

Here's a look at the major movers and shakers of D-Street through the session.

Orchid Chemicals surged nearly 10% on the back of reports that the CDR empowered group has approved the company's debt restructuring propos...

As a proxy fight for the control of drug maker Orchid intensifies in the stock market, a key weapon in founder K Raghavendra Rao’s arsenal ...